

Headline: **Osteoporosis diagnosis revolutionized**

Ingress: *In a key clinical study recently published in Osteoporosis International, Demetech AB, Stockholm, has clearly demonstrated that their proprietary DXL technology and heel measurement can be used applying WHO criteria for diagnosis of osteoporosis. This will dramatically simplify the diagnosis of osteoporosis in primary care.*

Copy: The lifetime prevalence for osteoporosis is more than 30% for women and 13% for men. In order to combat this disease and its severe consequences for those affected, WHO, issued diagnostic guidelines in 1994. Several initiatives on governmental level are currently driven in the USA and in the EU to raise awareness and improve patient care.

Lack of access to diagnostic equipment is one of the limiting factors in efficiently managing this disease. The only reliable and endorsed technology has been restricted to a few large hospitals.

With the publication of this pivotal study in the scientific renown journal Osteoporosis International its firmly established that the Swedish invention can be used for diagnosis of osteoporosis. The study named “Prevalence of osteoporosis using bone mineral measurements at the calcaneus by dual X-ray and laser (DXL)” made by Associate Professor Ragnar Kullenberg, Göteborg University and Demetech AB and Professor Jan Falch, Center of Endocrinology, Aker University Hospital, Norway is available online at www.springer.com

The first product launched based on the DXL technology is DXL Calscan. It’s a mobile and easy to use instrument, with its superior accuracy and ease of handling allows diagnosis to be made in primary care environment. Many more patients can enjoy benefits and receive proper care as a result, says Anders Reifeldt, President and CEO of Demetech AB.

For more information contact Anders Reifeldt, President and CEO of Demetech AB.

Phone: +46 8 555 792 00
Mobile: +46 733 10 50 91
E-mail: anders.reifeldt@demetech.se

You are also welcome to visit www.demetech.com, for more information about Demetech AB and the DXL technology.

For more information on Osteoporosis and initiatives to combat the disease:

www.osteofound.org	Osteoporosis International Foundation
www.nof.org	National Osteoporosis Foundation, USA
www.asbmr.org	American Society of Bone and Mineral Research

Demetech AB

Demetech AB is a Swedish company that develops and markets systems for the diagnosis and early detection of osteoporosis.

The company was founded by Associate Professor Ragnar Kullenberg and Anders Ullberg, R&D Manager in 1996. The technical development resulted in the first launch of DXL Calscan in Sweden in 2001 and Europe in 2002. Principal owners are Scandinavian Life Science, Karolinska Investment Fund, Stena Sessan Rederier AB and the founders. Demetech is located in Stockholm, Sweden.

www.demetech.com

The DXL technology – patented technology for measuring bone density

Dual X-ray and Laser, commonly called DXL, was invented by a team of Swedish doctors, researchers and engineers.

It combines a dual-wavelength X-ray source with laser definition of the measurement area. The result is that soft tissue and fatty tissue are excluded from the bone mineral density reading, resulting in extremely accurate measurements. DXL offers completely new capabilities for reliable diagnosis of osteopenia and osteoporosis, long before the first fracture might occur. The measurements are highly predictive for all types of brittle bone fractures in the hip, spine wrist and other bones.

DXL Calscan

DXL Calscan is the first so called peripheral instrument based on this technology. DXL Calscan is a portable, mobile and easy to use diagnostic tool, offering unsurpassed accuracy and reliability compared to other peripheral instruments.